Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
GlobeNewswire
The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety..
